1. ALLA AKTIER
  2. NYHETER
  3. SPRINT BIOSCIENCE

Sprint Bioscience

Nyheter Sprint Bioscience Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Sprint Bioscience appoints Jenni Björnulfson as CFO

MARKN.

Sprint Bioscience AB (publ) today announces that Jenni Björnulfson has been appointed chief Financial Officer (CFO) of the company. With extensive and diverse experience in both life science and finance, Jenni Björnulfson will, upon assuming her position on May 4, join the company’s executive management team.

Jenni Björnulfson has previously held several senior positions as CFO, CEO, and board member within the biotech and pharmaceutical industries. In addition, she has many years of experience working in the financial markets, where she has served both as an equity analyst and in corporate finance with a focus on life science.

“Jenni Björnulfson’s broad background in both life science and finance makes her well equipped to contribute to our continued growth. We look forward to further strengthening the organization with her expertise and experience,” said Johan Emilsson, CEO of Sprint Bioscience.
 

For further information, kindly contact:

Johan Emilsson, CEO, Sprint Bioscience
Phone: +46 (8) 411 44 55
Email: johan.emilsson@sprintbioscience.com

About Sprint Bioscience AB (publ)

Sprint Bioscience develops small molecule first-in-class drug programs with a focus on oncology. With a fragment-based drug development method, the company develops drug programs in a time- and resource-efficient manner. The programs enter partnerships through licensing agreements, asset acquisitions, or research collaborations with global pharmaceutical companies during the pre-clinical phase and the company has successfully formed several agreements. The Sprint Bioscience share is listed on the Nasdaq First North Premier Growth Market and trades under the ticker symbol SPRINT. The company is based in Stockholm with operations located in Huddinge. Further information is available on the company website; www.sprintbioscience.com. Certified Advisor is FNCA Sweden AB, www.fnca.se.

Attachments

Sprint Bioscience appoints Jenni Björnulfson as CFO

Datum 2026-04-01, kl 10:55
Källa MFN
Bifogade filer
Sprint Bioscience appoints Jenni Björnulfson as CFO